Evidence map›Paper›PMID 35813941›Full record

ReviewFrontiers in aging neuroscience2022

Epigenetics in Alzheimer's Disease.

Xiaodie Gao, Qiang Chen, Hua Yao, Jie Tan, Zheng Liu, Yan Zhou, Zhenyou Zou

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in aging neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. The Role of Hydrogen Sulfide (HInternational journal of molecular sciences · 2023
    Pooled it
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Blood gene expression network expression strongly relates to brain amyloid burden.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. The Hallmarks of Ageing in Microglia.Cellular and molecular neurobiology · 2025
    Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xiaodie GaoGuangxi Key Lab of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, China.
Qiang ChenDepartment of Scientific Research, Brain Hospital of Guangxi Zhuang Autonomous Region, Liuzhou, China.
Hua YaoGuangxi Key Lab of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, China.
Jie TanGuangxi Key Lab of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, China.
Zheng LiuGuangxi Key Lab of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, China.
Yan ZhouGuangxi Key Lab of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, China.
Zhenyou ZouGuangxi Key Lab of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is a neurodegenerative disease with unknown pathogenesis and complex pathological manifestations. At present, a large number of studies on targeted drugs for the typical pathological phenomenon of AD (Aβ) have ended in failure. Although there are some drugs on the market that indirectly act on AD, their efficacy is very low and the side effects are substantial, so there is an urgent need to develop a new strategy for the treatment of AD. An increasing number of studies have confirmed epigenetic changes in AD. Although it is not clear whether these epigenetic changes are the cause or result of AD, they provide a new avenue of treatment for medical researchers worldwide. This article summarizes various epigenetic changes in AD, including DNA methylation, histone modification and miRNA, and concludes that epigenetics has great potential as a new target for the treatment of AD.

Indexed as

acetylationAlzheimer’s diseaseepigeneticsmethylationubiquitination

Identifiers

PMID35813941
PMCPMC9260511

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.